DK1713501T3 - Behandling af neurodegenerative sygdomme ved anvendelse af GPR49 - Google Patents

Behandling af neurodegenerative sygdomme ved anvendelse af GPR49

Info

Publication number
DK1713501T3
DK1713501T3 DK04803345T DK04803345T DK1713501T3 DK 1713501 T3 DK1713501 T3 DK 1713501T3 DK 04803345 T DK04803345 T DK 04803345T DK 04803345 T DK04803345 T DK 04803345T DK 1713501 T3 DK1713501 T3 DK 1713501T3
Authority
DK
Denmark
Prior art keywords
gpr49
secretase
interacting molecule
treatment
beta
Prior art date
Application number
DK04803345T
Other languages
English (en)
Inventor
Carsten Hopf
Gerard Drewes
Heinz Ruffner
Original Assignee
Cellzome Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellzome Ag filed Critical Cellzome Ag
Application granted granted Critical
Publication of DK1713501T3 publication Critical patent/DK1713501T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK04803345T 2004-01-29 2004-11-29 Behandling af neurodegenerative sygdomme ved anvendelse af GPR49 DK1713501T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP04001894 2004-01-29
EP04001895 2004-01-29
EP04007447 2004-03-26
EP2004004889 2004-05-07
EP2004004891 2004-05-07
PCT/EP2004/013539 WO2005074980A1 (en) 2004-01-29 2004-11-29 Treatment of neurodegenerative diseases by the use of gpr49

Publications (1)

Publication Number Publication Date
DK1713501T3 true DK1713501T3 (da) 2008-05-26

Family

ID=38556372

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04803345T DK1713501T3 (da) 2004-01-29 2004-11-29 Behandling af neurodegenerative sygdomme ved anvendelse af GPR49

Country Status (11)

Country Link
US (1) US20080025969A1 (da)
EP (1) EP1713501B1 (da)
JP (1) JP2007525491A (da)
AT (1) ATE383870T1 (da)
AU (1) AU2004315111B2 (da)
CA (1) CA2554353A1 (da)
DE (1) DE602004011400T2 (da)
DK (1) DK1713501T3 (da)
ES (1) ES2300852T3 (da)
PT (1) PT1713501E (da)
WO (2) WO2005074980A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
AU2006335053A1 (en) * 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP2022848A1 (en) 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
WO2010016766A2 (en) * 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Antibodies recognizing endogenous human lgr5 and/or lgr6
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
AU2010203356B2 (en) 2009-01-09 2015-11-26 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
DK2590647T3 (da) * 2010-07-07 2018-02-12 Univ Texas Pro-neurogene forbindelser
AU2013305591B2 (en) 2012-08-24 2017-04-13 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
AU2013372386B2 (en) 2013-01-10 2018-04-19 Merck Patent Gmbh Piperidinylcarbazole as antimalarial
WO2015070234A2 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
JP2017519795A (ja) 2014-07-04 2017-07-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 抗寄生生物活性を有するアゼパニル（ａｚｅｐａｎｙｌ）誘導体およびそれを含む医薬組成物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) * 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
AU4589297A (en) * 1996-10-07 1998-05-05 Scios Inc. Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
JP2002535289A (ja) * 1999-01-22 2002-10-22 ドウアリング，マシユー・ジヨン 神経疾患のワクチン媒介治療
DE19941039A1 (de) * 1999-08-28 2001-03-01 Boehringer Ingelheim Pharma gamma-Sekretase in vitro Testsystem
GB0005894D0 (en) * 2000-03-10 2000-05-03 Glaxo Group Ltd Assay
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
EP1354950A4 (en) * 2000-12-28 2005-01-12 Asahi Kasei Pharma Corp ACTIVATION GENE OF NF-KB
AU2002228316A1 (en) * 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
AU2003245987A1 (en) * 2002-06-26 2004-02-02 Cellzome Ag Components of the presenilin-complex
EP1380644A1 (en) * 2002-07-08 2004-01-14 Kylix B.V. The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role
US7056685B1 (en) * 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
US7189539B2 (en) * 2003-11-25 2007-03-13 Bristol-Myers Squibb Company Polynucleotide encoding a human relaxin receptor, HGPRBMY5v1

Also Published As

Publication number Publication date
DE602004011400T2 (de) 2009-01-22
PT1713501E (pt) 2008-04-30
AU2004315111B2 (en) 2010-03-04
AU2004315111A1 (en) 2005-08-18
WO2005074980A1 (en) 2005-08-18
DE602004011400D1 (de) 2008-03-06
ATE383870T1 (de) 2008-02-15
CA2554353A1 (en) 2005-08-18
EP1713501A1 (en) 2006-10-25
ES2300852T3 (es) 2008-06-16
WO2005074971A1 (en) 2005-08-18
JP2007525491A (ja) 2007-09-06
EP1713501B1 (en) 2008-01-16
US20080025969A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
DK1713501T3 (da) Behandling af neurodegenerative sygdomme ved anvendelse af GPR49
EA201070247A1 (ru) Ингибиторы протеасом
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
NO20061122L (no) 2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer
NO20080318L (no) Anvendelse av enkelt dose av CD-20-spesifikke bindingsmolekyler
NO20064362L (no) Forbindelser, farmaseutiske sammensetninger og fremgangsmater for anvendelse i behandling av metabolske sykdommer
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DK1567488T3 (da) Hydroxyethylaminderivater til behandling af Alzheimers sygdom
EA200801565A1 (ru) Производные пиримидиниларилмочевины в качестве ингибиторов фактора роста фибробластов ( fgf-фактора )
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
NO20072092L (no) Sulfonamidforbindelser
ATE383337T1 (de) 1-(1h-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1- phenylpropan-2-olderivate und verwandte verbindungen als modulatoren der norepinephrin- (ne-) und der serotonin-(5-ht-) aktivität und der monoaminwiederaufnahme zur behandlung von vasomotorischen symptomen (vms)
EA200702567A1 (ru) Ингибиторы дипептидил пептидазы iv, основанные на пирролопиридине
MA31858B1 (fr) N-phenyl-bipyrrolidine-carboxamides substitues et utilisation therapeutique de ceux-ci
ATE413406T1 (de) Benzothiazol-, thiazolopyridin-, benzooxazol- und oxazolopyridin-derivate als verbindungen zur behandlung von diabetes
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DE602005027388D1 (de) Malonsäureamidderivate als inhibitoren von g-sekretase zur behandlung von alzheimer-krankheit
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
CY1109975T1 (el) Παρα-αλκυλ-υποκατεστημενα αμιδια ν-(4-υδροξυ-3-μεθοξυ-βενζυλο) κιναμμωμικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
ATE538796T1 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
WO2005075632A3 (en) Treatment of neurodegenerative diseases by the use of atp7a-modulators
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины